The case for & against
Bull & Bear analysis
Bearish
Nyxoah (NASDAQ: NYXH) is a leading innovator in the medical device sector, specializing in therapeutic solutions for obstructive sleep apnea (OSA) through its unique Genio system. Positioned as a front-runner in hypoglossal nerve stimulation technology, Nyxoah aims to disrupt traditional OSA treatments, such as CPAP, by offering a more patient-friendly option. The company's recent FDA approval and ongoing U.S. commercialization highlight its potential to capture significant market share in a growing healthcare landscape.
Bull says
- ↑Q2 2026 revenue €7.7M (+21% sequential) reaffirms €36–40M guidance
- ↑Genio system secured 100% prior authorization approval for reimbursements
- ↑U.S. launch ramp with expanded salesforce targets high-volume accounts
- ↑Book-to-price ratio 1.34 indicates potential undervaluation
- ↑Cash reserves €97.8M fund commercialization and surgeon training
- ↑62 new surgeons trained in Q2 2026 supports market penetration
Bear says
- ↓Operating loss €20.6M in Q1 2025 highlights elevated OPEX burn
- ↓Negative profitability exposure hinders margin recovery
- ↓High share-price volatility and elevated short interest signal skepticism
- ↓Intense competition from Inspire and Medtronic threatens market share
- ↓Analyst revisions trending lower as growth targets face execution risk
- ↓Cash runway pressure persists without sustained revenue ramp
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-14-2026neutral
Transcript signals
Bull points
- we are feeling confident that we will obtain the FDA approval
- So it gives the patient the comfort and it gives the physician the option to gradually ramp up stimulation, enabling him also to treat patients that might be sensitive previously when treated with stimulation that now all of a sudden become eligible.
- So combining those two upgrades in one software upgrade is really contributing to our mission in having a patient-centered solution.
Bear points
- From an FDA timeline perspective, we've taken steps to defer costs and investments until our FDA approval is achieved and received.
- we had a few orders that we didn't ship out this past quarter because we wanted the customers, and the customers wanted to have the latest upgraded activation chips for their customers.
- We also saw our competitor in the first quarter also posted a bid single digits decline in the international market.
Read full transcript analysis ›